Stockreport

Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]

Avidity Biosciences, Inc.  (RNA) 
PDF The company's market cap valuation is approximately $1.5 billion. Its IPO raised $259 million in June 2020 at $18 per share. Avidity has attracted major pharma compan [Read more]